breast neoplasms

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Hanwen Wang, Huilin Ma, Richard J Sové, Leisha A Emens, Aleksander S Popel

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e002100; DOI: 10.1136/jitc-2020-002100
TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, Sam Marks, Sonya Chew, Michael Conroy, Caitriona Goggin, Colm MacEochagain, John Kennedy, Sophie Lucas, David K Finlay, Clair M Gardiner

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e002044; DOI: 10.1136/jitc-2020-002044
MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Nami Yamashita, Mark Long, Atsushi Fushimi, Masaaki Yamamoto, Tsuyoshi Hata, Masayuki Hagiwara, Atrayee Bhattacharya, Qiang Hu, Kwok-Kin Wong, Song Liu, Donald Kufe

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e002115; DOI: 10.1136/jitc-2020-002115
Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
Demi Brownlie, Dahlia Doughty-Shenton, Daniel YH Soong, Colin Nixon, Neil O Carragher, Leo M Carlin, Takanori Kitamura

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001740; DOI: 10.1136/jitc-2020-001740
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Mariya Rozenblit, Richard Huang, Natalie Danziger, Priti Hegde, Brian Alexander, Shakti Ramkissoon, Kim Blenman, Jeffrey S Ross, David L Rimm, Lajos Pusztai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (2) e001558; DOI: 10.1136/jitc-2020-001558
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Chiara Massa, Thomas Karn, Carsten Denkert, Andreas Schneeweiss, Claus Hanusch, Jens-Uwe Blohmer, Dirk-Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marme, Jens Huober, Volkmar Müller, Christian Schem, Anja Mueller, Elmar Stickeler, Katharina Biehl, Peter A Fasching, Michael Untch, Sibylle Loibl, Karsten Weber, Barbara Seliger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (2) e001261; DOI: 10.1136/jitc-2020-001261
Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway
Kim M van Pul, Ronald J C L M Vuylsteke, Monique T A de Beijer, Rieneke van de Ven, M Petrousjka van den Tol, Hein B A C Stockmann, Tanja D de Gruijl

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000761; DOI: 10.1136/jitc-2020-000761
Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity
Natasha D Sheybani, Alexandra R Witter, Eric A Thim, Hideo Yagita, Timothy N J Bullock, Richard J Price

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e001008; DOI: 10.1136/jitc-2020-001008
TFEB is a master regulator of tumor-associated macrophages in breast cancer
Yong Li, Johnie Hodge, Qing Liu, Junfeng Wang, Yuzhen Wang, Trent D Evans, Diego Altomare, Yongzhong Yao, E Angela Murphy, Babak Razani, Daping Fan

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000543; DOI: 10.1136/jitc-2020-000543
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu, Qiang Liu, Ying Li, Qian Li, Fengxi Su, Herui Yao, Shicheng Su, Quanren Wang, Liang Jin, Ying Wang, Wan Yee Lau, Zefei Jiang, Erwei Song

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000696; DOI: 10.1136/jitc-2020-000696

Main menu

breast neoplasms

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

breast neoplasms

Pages